Viz.ai: Viz.ai to Collaborate with Guardant Health to Improve Lung Cancer Detection, Diagnosis, and Treatment

Viz.ai announced a proposed collaboration with Guardant Health, Inc. The collaboration aims to help oncologists diagnose lung cancer earlier and make more informed treatment decisions to improve patient outcomes, reflecting the companies? shared commitment to leveraging technology to close critical gaps in cancer care and streamline the patient journey. Nearly 40% of lung cancer patients are estimated not to be receiving guideline-directed medical therapy. Delays in diagnosis, testing, and appropriate treatment increase the risk of lung cancer progression to advanced-stage disease and can contribute to higher mortality rates. The intent of the proposed collaboration between Viz.ai and Guardant is to address clinical practice gaps along the lung cancer patient journey by facilitating timely biomarker testing with the Guardant360® CDx liquid biopsy, thereby accelerating time to precision diagnosis and optimal treatment selection. The Viz.ai One platform leverages machine learning algorithms to analyze data from imaging, the EHR and other tests and deliver real-time, actionable insights and automated assessments to accelerate diagnosis and treatment. Viz.ai acts as a safety net in 1,700 hospitals to automatically identify patients with disease and direct them to the right specialist and the right treatment. Viz.ai announced a proposed collaboration with Guardant Health, Inc. The collaboration aims to help oncologists diagnose lung cancer earlier and make more informed treatment decisions to improve patient outcomes, reflecting the companies? shared commitment to leveraging technology to close critical gaps in cancer care and streamline the patient journey. Nearly 40% of lung cancer patients are estimated not to be receiving guideline-directed medical therapy. Delays in diagnosis, testing, and appropriate treatment increase the risk of lung cancer progression to advanced-stage disease and can contribute to higher mortality rates. The intent of the proposed collaboration between Viz.ai and Guardant is to address clinical practice gaps along the lung cancer patient journey by facilitating timely biomarker testing with the Guardant360® CDx liquid biopsy, thereby accelerating time to precision diagnosis and optimal treatment selection. The Viz.ai One platform leverages machine learning algorithms to analyze data from imaging, the EHR and other tests and deliver real-time, actionable insights and automated assessments to accelerate diagnosis and treatment. Viz.ai acts as a safety net in 1,700 hospitals to automatically identify patients with disease and direct them to the right specialist and the right treatment.